De-Identified Health Data Market Report 2025

The de-identified health data market size has grown rapidly in recent years. It will grow from $8.2 billion in 2024 to $9.2 billion in 2025 at a compound annual growth rate (CAGR) of 12.2%. The growth during the historic period is attributed to the increasing adoption of electronic health records, rising awareness of patient data privacy, greater use of healthcare analytics, expanding research in population health management, growth of health information technology systems, and increased utilization of data in clinical trials.

The de-identified health data market size is expected to see rapid growth in the next few years. It will grow to $14.4 billion in 2029 at a compound annual growth rate (CAGR) of 11.8%. The growth during the forecast period is driven by the expanding application of artificial intelligence in healthcare, rising demand for real-world evidence in drug development, growing focus on the secondary use of health data, increasing demand for privacy-enhancing technologies, and the rising need for precision medicine. Key trends in the forecast period include the development of data privacy protocols, creation of machine learning pipelines, integration with electronic health records, incorporation with population health platforms, and innovations in data anonymization techniques.

The growing adoption of electronic health records is expected to support the expansion of the de-identified health data market in the coming years. Electronic health records refer to digital versions of patients’ complete medical histories, including diagnoses, treatments, medications, laboratory results, and other health-related information that are securely stored and accessible by authorized healthcare professionals. The increasing use of electronic health records is driven by their ability to improve patient care and safety through accurate and real-time access to comprehensive clinical data. De-identified health data enhances the functionality of electronic health records by enabling secure data sharing and the application of advanced analytics while ensuring patient privacy. This supports better clinical decision-making and contributes to improved healthcare outcomes. For example, in June 2022, the Department of Health and Social Care, a government department based in the United Kingdom, reported that all NHS trusts are expected to implement electronic health records by March 2025, up from a ninety percent adoption rate in December 2023. As a result, the growing use of electronic health records is contributing to the expansion of the de-identified health data market.

Key companies in the de-identified health data market are developing new technologies such as real-world biomarker coverage applications to support data-driven healthcare decision-making. A real-world biomarker coverage application uses de-identified patient data to monitor and evaluate biomarker trends and their effectiveness in varied populations outside of controlled clinical environments. This enables healthcare providers and researchers to gain valuable insights into treatment outcomes and disease patterns. For instance, in July 2025, Datma Inc., a healthcare technology company based in the United States, introduced the Federated Biomarker Explorer, a free application intended for pharmaceutical teams to rapidly assess real-world biomarker coverage within Datma’s network of data contributors. This tool offers cohort-level insights into biomarker distribution and allows teams to evaluate data availability without entering contracts or requiring technical support. It also enables secure integration of users’ own datasets for comparison and supports early feasibility assessments by applying clinical and demographic filters to confirm the presence of needed patient populations before proceeding with studies.

In July 2025, Datavant Inc., a health information technology company based in the United States, acquired Aetion Inc. for an undisclosed amount. This acquisition is aimed at strengthening Datavant’s capabilities in real-world evidence by incorporating Aetion’s advanced analytics platform. The integration is intended to offer healthcare and life sciences organizations a comprehensive solution for producing high-quality, regulatory-grade insights using de-identified health data. Aetion Inc. is a real-world evidence platform also based in the United States, known for providing de-identified health data solutions through tools such as Aetion Generate.

Major players in the de-identified health data market are UnitedHealth Group Incorporated, Oracle Corporation, IQVIA Holdings Inc, ICON Public Limited Company, Datavant Inc, Premier Inc., iMerit Technology Services Pvt. Ltd., Tempus Labs Inc., Medidata Solutions Inc., Veradigm Inc., Flatiron Health, Merative LP, Komodo Health Inc., Shaip Inc., Truveta Inc., Evidation Health Inc., TriNetX Inc., Clarify Health Solutions Inc., Akrivia Health Ltd., Gradient Health Inc.

North America was the largest region in the de-identified health data market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in de-identified health data report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the de-identified health data market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

De-identified health data refers to patient information from which all personally identifiable details, such as names, addresses, and social security numbers, have been removed, making it impossible to trace the data back to any individual. It enables healthcare providers, researchers, and organizations to analyze trends, improve treatments, and develop effective public health strategies while maintaining patient privacy.

The primary types of de-identified health data include clinical data, genomic data, patient demographics, prescription data, hospital and provider data, and pharmacogenomic data. Clinical data consists of health-related information collected during healthcare delivery, including medical history, diagnoses, treatments, laboratory results, and outcomes. This data is applied across multiple areas, including clinical research and trials, public health, precision medicine, health economics and outcomes research (HEOR), population health management, drug discovery and development, healthcare quality improvement, insurance underwriting and risk assessment, and more. Key end users include pharmaceutical companies, biotechnology firms, healthcare providers, insurance companies and payers, research institutions, government agencies, and others.

The de-identified health data market research report is one of a series of new reports that provides de-identified health data market statistics, including de-identified health data industry global market size, regional shares, competitors with a de-identified health data market share, detailed de-identified health data market segments, market trends and opportunities, and any further data you may need to thrive in the de-identified health data industry. This de-identified health data market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The de-identified health data market includes revenues earned by entities by providing services such as medical research and clinical studies, machine learning development, public health and epidemiology, healthcare system improvement, and health economics and policy planning. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.